PER-005-12未知未知
AN OPEN-LABEL, SINGLE-ARM, EXTENSION STUDY TO DEMONSTRATE LONG-TERM EFFICACY AND SAFETY OF CT-P13 WHEN CO-ADMINISTERED WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO WERE TREATED WITH INFLIXIMAB (REMICADE OR CT-P13) IN STUDY CT-P13 3.1.
Celltrion, Inc.,0 个研究点目标入组 11 人开始时间: 2012年5月29日最近更新:
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75（—）
入选标准
- •EACH PATIENT MUST MEET ALL THE FOLLOWING CRITERIA TO BE ENROLLED IN THIS STUDY:
- •1. PATIENT WHO HAS COMPLETED THE SCHEDULED VISITS, NCLUDING THE END-OF-STUDY VISIT, IN STUDY CT-P13 3.1.
- •2. PATIENT WHO HAS NOT HAD ANY MAJOR PROTOCOL VIOLATION IN STUDY CT-P13 3.1.
- •3. PATIENT IS PERMITTED TO ENTER THE EXTENSION STUDY IF, IN THE OPINION OF THEIR GENERAL PRACTITIONER OR THE INVESTIGATOR, THE PATIENT WILL CONTINUE TO GAIN BENEFIT FROM TREATMENT IN THE EXTENSION STUDY. LOCAL GUIDELINES FOR PATIENT TREATMENT WILL BE FOLLOWED.
- •4. PATIENT (OR LEGAL GUARDIANS, IF APLICABLE) IS INFORMED OF THE FULL NATURE AND PURPOSE OF THE STUDY, INCLUDING POSSIBLE RISKS AND SIDE EFFECTS, AND GIVEN AMPLE TIME AND OPPORTUNITY TO READ AND UNDERSTAND THIS INFORMATION, AND HAS SIGNED AND DATED THE WRITTEN INFORMED CONSENT BEFORE INCLUSION IN THE EXTENSION STUDY.
- •5. BOTH MALE AND FEMALE PATIENTS AND THEIR PARTNERS OF CHILDBEARING POTENCIAL MUST AGREE TO USE 2 MEDICALLY ACCEPTED METHODS OF CONTRACEPTION (EG. BARRIER CONTRACEPTIVES [MALE CONDOM, FEMALE CONDOM, OR DIAPHRAGM WITH A SPERMICIDAL GEL], HORMONAL CONTRACEPTIVES [IMPLANTS, INJECTABLES, COMBINATION ORAL CONTRACEPTIVES, TRANSDERMAL PATCHES, OR CONTRACEPTIVE RINGS], AND INTRAUTERINE DEVICES) DURING THE COURSE OF THE STUDY AND FOR 6 MONTHS FOLLOWING DISCONTINUATION OF STUDY TREATMENT (EXCLUDING WOMEN WHO ARE NOT OF CHILDBEARING POTENTIAL AND MEN WHO HAVE BEEN STERILIZED).
- •6. BOTH MALE AND FEMALE PATIENTS AN THEIR PARTNERS OF CHILDBEARING POTENTIAL
排除标准
- •PATIENTS MEETING ANY OF THE FOLLOWING CRITERIA WILL BE EXCLUDED FROM THE STUDY:
- •1. PATIENT WHO HAS BEEN WITHDRAWN FROM STUDY CT-P13 3.1 FOR ANY REASON.
- •2. PATIENT WHO, AT THE TIME OF PROVIDING INFORMED CONSENT, HAS ANY ONGOING MEDICAL ISSUES SUCH AS SERIOUS ADVERSE EVENTS (SAEs) OR INTOLERANCE ISSUES HAT MEAN CONTINUATION IN THIS EXTENSION STUDY COULD BE DETRIMENTAL TO THEIR HEALTH, IN THE OPINION OF THE INVESTIGADOR.
- •3. PATIENT WHO PLANS TO PARTICIPATE IN A STUDY WITH AN INVESTIGATIONAL DRUG DURING THE PERIOD OF THIS EXTENSION STUDY.
- •4. FEMALE PATIENT WHO IS PLANNING TO BECOME PREGNANT OR BREASTFEED WITHIN THE PERIOD OF THE STUDY.
- •5. PATIENT WHO PLANS TO RECEIVE OR LIVE-ATTENUATED VACCINATION OR WHO IS SCHEDULED TO RECEIVE A LIVE OR LIVE-ATTENUATED VACCINATION DURING THE PERIOD OF THIS STUDY. KILLED VACCINES ARE ACCEPTABLE DURING THE STUDY.
- •6. PATIENT WHO, IN THE OPININ OF THEIR GENERAL PRACTITIONER OR INVESTIGATOR, SHOULD NOT PARTICIPATE IN THIS EXTENSION STUDY FOR WHATEVER REASON.
- •7. PATIENT WHO IS RECEIVING ANY SURGICAL PROCEDURE, INCLUDING BONE OR JOINT SURGERY OR SYNOVECTOMY (INCLUDING JOINT FUSION OR REPLACEMENT) WITHIN 12 WEEKS PRIOR TO THE TIME OF PROVIDING INFORMED CONSENT OR PLANNED WITHIN 6 MONTHS AFTER THE TIME OF PROVIDING INFORMED CONSENT.
- •8. PATIENT WHO, AT THE TIME OF PROVIDING INFORMED CONSENT, IS TAKING, IS PLANNING TO TAKE, OR IS REQUIRED TO TAKE DURING THE COURSE OF THIS STUDY ANY OF THE FOLLOWING CONCOMITANT MEDICATIONS:
- •. CORTICOSTEROIDS
研究者
相似试验
进行中（未招募）
1 期
Evaluating the long-term Safety and Efficacy effects of CT-P13 together with methotrexate in patients with arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-004468-31-GBCELLTRION, Inc302
进行中（未招募）
不适用
Comparing the long-term effects of CT-P13 with remicade together with methotrexate in patients with arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-004468-31-SKCELLTRION, Inc
进行中（未招募）
不适用
ong-term safety and effectivenss CT-P13 together with methotrexate in patients with arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-004468-31-LVCELLTRION, Inc617
进行中（未招募）
不适用
Comparing the long-term effects of CT-P13 with remicade together with methotrexate in patients with arthritisRheumatoid ArthritisEUCTR2011-004468-31-ITCELLTRION, INC.617
进行中（未招募）
不适用
Evaluating the long-term Safety and Efficacy effects of CT-P13 together with methotrexate in patients with arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-004468-31-LTCELLTRION, Inc617